{"id":465,"date":"2024-10-22T21:52:06","date_gmt":"2024-10-22T21:52:06","guid":{"rendered":"https:\/\/event.eortc.org\/ena2024\/?page_id=465"},"modified":"2024-10-23T10:00:04","modified_gmt":"2024-10-23T10:00:04","slug":"latest-news","status":"publish","type":"page","link":"https:\/\/event.eortc.org\/ena2024\/latest-news\/","title":{"rendered":"Latest news"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4%;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:75%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.56%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.56%;--awb-width-medium:75%;--awb-order-medium:0;--awb-spacing-right-medium:2.56%;--awb-spacing-left-medium:2.56%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"--awb-margin-bottom:40px;--awb-margin-top-small:10px;--awb-margin-right-small:0px;--awb-margin-bottom-small:10px;--awb-margin-left-small:0px;\"><h2 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">ENA 2024: Latest News<\/h2><\/div><div class=\"fusion-recent-posts fusion-recent-posts-1 avada-container layout-thumbnails-on-side layout-columns-1\"><section class=\"fusion-columns columns fusion-columns-1 columns-1\"><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:15+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2024\/2024\/10\/25\/digital-twin-prediction\/\">Scientists create cancer patients\u2019 \u2018digital twins\u2019 to predict how well treatments may work<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:15+01:00<\/span><span>October 25, 2024<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p>Friday 25 October 2024, Barcelona, Spain: Researchers have shown that they can accurately re-create clinical trials of new treatments using \u2018digital twins\u2019 of real cancer patients. The technology, called FarrSight\u00ae-Twin, which is based on algorithms [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:26+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2024\/2024\/10\/25\/patients-with-advanced-bladder-cancer-with-alterations-in-the-fgfr3-gene\/\">Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:26+01:00<\/span><span>October 25, 2024<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p> Friday 25 October 2024, Barcelona, Spain: Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:33+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2024\/2024\/10\/25\/key-genetic-mutations\/\">Researchers find key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:33+01:00<\/span><span>October 25, 2024<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p>Friday 25 October 2024, Barcelona, Spain: Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs. The yet-to-be-published findings are presented on Friday [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:40+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2024\/2024\/10\/25\/new-mini-protien-radiation-dose\/\">New \u2018mini-protein\u2019 carries radiation dose directly to tumours without harming healthy tissues<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:40+01:00<\/span><span>October 25, 2024<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p> Friday 25 October 2024, Barcelona, Spain: Researchers have shown for the first time that it is possible for a specially-designed \u2018mini-protein\u2019 to deliver a radiation dose directly to tumour cells expressing a protein on [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:48+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2024\/2024\/10\/24\/treatment-could-help-patients-with-rare-cancer\/\">Treatments used for HER2-positive breast cancers could help patients with rare gastrointestinal cancer<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:48+01:00<\/span><span>October 24, 2024<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p> Trial of tucatinib and trastuzumab also showed benefits for HER2-mutated breast cancer: Thursday 24 October 2024, Barcelona, Spain: Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/frince\/\" rel=\"author\">frince<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:57+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2024\/2024\/10\/23\/new-drug-delays-tumour\/\">New drug, WNTinib, delays tumour growth and improves survival in mouse models of children\u2019s liver cancer<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2024\/author\/frince\/\" rel=\"author\">frince<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2024-11-13T09:26:57+01:00<\/span><span>October 23, 2024<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p> Wednesday 23 October 2024, Barcelona, Spain:\u00a0A new drug called WNTinib can delay the growth of tumours and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children. This effect was [...]<\/p><\/div><\/article><\/section><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>yes<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-465","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/pages\/465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/comments?post=465"}],"version-history":[{"count":0,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/pages\/465\/revisions"}],"wp:attachment":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/media?parent=465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}